Nausea and Vomiting in Obesity (After GLP-1R Agonist Use)
VNDAVanda Pharmaceuticals Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for NEREUS™ (tradipitant) in Nausea and Vomiting in Obesity (After GLP-1R Agonist Use). The expected timing is based on the latest available company guidance and may change.
11/17/25– Reported topline results. Initiate Ph3 trial in H1 2026. 02/11/26:- Plans Phase 3 NEREUS program for GLP-1–induced vomiting in H1 2026 reiterated after positive Wegovy study. 04/08/26:- Thetis trial initiated; topline expected Q4 2026. Wegovy Phase 2 met endpoint with 50% vomiting reduction. 08/05/26:- Thetis Ph3 results for GLP-1 vomiting remain expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.